With the December 2014 announcement of Xarelto’s consolidated multi-district litigation (“MDL”), plaintiffs are anxious to hear the outcome of upcoming bellwether trials. The MDL consolidates two dozen lawsuits−with many more expected to be filed−all claiming similar bleeding complications associated with the dangerous anticoagulant, in a move that will help save costs and time for injured plaintiffs. Judges on the MDL panel held in their ruling that “there were several important common issues, including the adequacy of Xarelto’s warning label, the results of clinical studies and the alleged need for blood monitoring” that led to their decision to allow the cases to proceed together. An initial status conference on the litigation, which was transferred to the Eastern District of Louisiana, is reportedly scheduled for later in January 2015. Read more here.